Raytheon awarded $71 million in Navy contracts for missile systems
Investing.com -- British drugmaker GSK (NYSE:GSK) has submitted an application to the U.S. Food and Drug Administration (FDA) to extend the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, to adults under the age of 50 who are at higher risk of the disease.
The company announced the submission on Monday.
Arexvy is currently approved for older adults, and this application aims to make the vaccine available to a younger population with elevated risk factors for RSV.
RSV is a common respiratory virus that can cause serious illness, particularly in vulnerable populations.
The application represents GSK’s effort to broaden protection against RSV to additional at-risk groups.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.